openPR Logo
Press release

Ischemic Stroke Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie

05-22-2024 08:32 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Ischemic Stroke Market to Register Incremental Growth During

The Ischemic Stroke market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ischemic Stroke pipeline products will significantly revolutionize the Ischemic Stroke market dynamics.

DelveInsight's "Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ischemic Stroke, historical and forecasted epidemiology as well as the Ischemic Stroke market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Ischemic Stroke market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ischemic Stroke Market Forecast
https://www.delveinsight.com/sample-request/ischemic-stroke-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ischemic Stroke Market Report:
• The Ischemic Stroke market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2024, Aruna Bio has revealed intentions to commence a Phase I/II clinical study for AB126, aimed at addressing acute ischemic stroke, during the initial six months of 2024. This determination follows the clearance by the US Food and Drug Administration (FDA) of the company's investigational new drug (IND) application pertaining to its primary program, AB126.
• As per the study conducted by Edward C Jauch et. al., nearly 800,000 people suffer from strokes each year in the United States and 82-92% of these strokes are ischemic. Stroke is the fifth leading cause of adult death and disability
• According to the World Health Organization (WHO), an estimated 15 million individuals worldwide suffer from stroke each year. Of these, 5 million die, and another 5 million are left permanently disabled.
• As per Stroke Association of the United Kingdom, Up to 25% of childhood Ischemic strokes are linked to congenital heart disease
• Key Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others
• Key Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others
• The Ischemic Stroke epidemiology based on gender analyzed that men are at higher risk for Ischemic Stroke than women

Ischemic Stroke Overview
Ischemic Stroke (AIS) occurs when blood flow through a brain artery is blocked by a clot- amass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.

Get a Free sample for the Ischemic Stroke Market Report:
https://www.delveinsight.com/report-store/ischemic-stroke-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ischemic Stroke Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ischemic Stroke Epidemiology Segmentation:
The Ischemic Stroke market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Ischemic Stroke
• Prevalent Cases of Ischemic Stroke by severity
• Gender-specific Prevalence of Ischemic Stroke
• Diagnosed Cases of Episodic and Chronic Ischemic Stroke

Download the report to understand which factors are driving Ischemic Stroke epidemiology trends @ Ischemic Stroke Epidemiological Insights
https://www.delveinsight.com/sample-request/ischemic-stroke-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ischemic Stroke Market
The dynamics of the Ischemic Stroke market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Ischemic Stroke Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ischemic Stroke market or expected to get launched during the study period. The analysis covers Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ischemic Stroke Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ischemic Stroke Therapies and Key Companies
• BMS986177: Bristol-Myers Squibb
• LT-3001: Lumosa Therapeutics
• Elezanumab: Abbvie
• MultiStem: Athersys/Healios K.K.

To know more about Ischemic Stroke treatment, visit @ Ischemic Stroke Medications
https://www.delveinsight.com/sample-request/ischemic-stroke-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Ischemic Stroke Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others
• Key Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others
• Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
• Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Ischemic Stroke Market Access and Reimbursement

Discover more about therapies set to grab major Ischemic Stroke market share @ Ischemic Stroke market forecast
https://www.delveinsight.com/sample-request/ischemic-stroke-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ischemic Stroke Market Report Introduction
2. Executive Summary for Ischemic Stroke
3. SWOT analysis of Ischemic Stroke
4. Ischemic Stroke Patient Share (%) Overview at a Glance
5. Ischemic Stroke Market Overview at a Glance
6. Ischemic Stroke Disease Background and Overview
7. Ischemic Stroke Epidemiology and Patient Population
8. Country-Specific Patient Population of Ischemic Stroke
9. Ischemic Stroke Current Treatment and Medical Practices
10. Ischemic Stroke Unmet Needs
11. Ischemic Stroke Emerging Therapies
12. Ischemic Stroke Market Outlook
13. Country-Wise Ischemic Stroke Market Analysis (2019-2032)
14. Ischemic Stroke Market Access and Reimbursement of Therapies
15. Ischemic Stroke Market drivers
16. Ischemic Stroke Market barriers
17. Ischemic Stroke Appendix
18. Ischemic Stroke Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dermatitis Seborrheic Market https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastro Intestinal Bleeding Market https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
DelveInsight's "Gastro Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastro Intestinal Bleeding, historical and forecasted epidemiology as well as the Gastro Intestinal Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ischemic Stroke Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie here

News-ID: 3508779 • Views:

More Releases from DelveInsight Business Research

Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Pfizer, AstraZeneca, Sermonix Pharmaceuticals, Novartis
Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epide …
(Albany, USA) DelveInsight's "Breast Cancer Biomarker Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Breast Cancer Biomarker, historical and forecasted epidemiology as well as the Breast Cancer Biomarker market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Breast Cancer Biomarker market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, C …
(Albany, USA) As per DelveInsight's assessment, globally, Murine Double Minute 2 (MDM2) Inhibitor pipeline constitutes key companies continuously working towards developing Murine Double Minute 2 (MDM2) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Murine Double Minute 2 (MDM2) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Murine
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline …
(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Interstitial Lung Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market. The Interstitial Lung Disease
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and companies by DelveInsight | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechan …
(Albany, USA) As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Myopia Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis

All 5 Releases


More Releases for Stroke

Global Stroke Imagine Processing Software Market 2021 | Increasing Number of Str …
Stroke Imagine Processing Software Market Snapshot Global Stroke Imagine Processing Software Market 2021 debates the report moreover centers around global giant manufacturers of the Stroke Imagine Processing Software with dynamic information like company profiles, market segmentation statistics, demanding situations and limitations, industry value, cost, sales, income, and much more information. This study provides key facts at the state of the industry and is a valuable supply of steerage and path for
Stroke Management Market Size To Reach USD 36.75 Billion, Globally, By 2023 | Di …
Asia-Pacific is expected to grow with the highest market share during the analysis period and would provide high opportunities for the market players. The global stroke management market was valued at $22,581 million in 2016, and is estimated to reach $36,756 million by 2023, growing at a CAGR of 7.1% from 2017 to 2023. The diagnostics segment held more than five-seventh share of the total market in 2016. Download Free Report Sample
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to
Ischemic Stroke Market Stoking High at a CAGR of 8.3% - Stroke Statistics, Young …
Detail Analysis of “Global Ischemic strokes Market” with respect to region specific market growth and competitive analysis on the basis of major players present in the market. The study also provides a comprehensive review of restraints, market dynamics and drivers. – Outlet till 2023 Key Players for Global Ischemic strokes Market: The emergence of new and cost-effective medication options for the treatment of ischemic stroke could open up new opportunities to the
Stroke Management Market By Application Ischemic Stroke and Hemorrhagic Stroke
The advancements in technology and facilities to diagnose stroke and discovery of novel drugs will drive growth of stroke management market. Technologies such as robotic-assisted angiography or exoskeleton soft suit for rehabilitation are the upcoming future of stroke management market. Moreover, an idea of Mobile Stroke Treatment Units (MSTU) was introduced in Germany in 2003 and was used in Berlin for the first time in 2008. The Prehospital Acute Neurological